Europe Biosimilars Market Size, Share & Industry Trends Analysis Report By Application (Oncology Diseases, Blood Disorders, Chronic & Autoimmune Diseases and Others), By Type, By Country and Growth Forecast, 2022 - 2028
The Europe Biosimilars Market would witness market growth of 23.6% CAGR during the forecast period (2022-2028).
The prevalence of autoimmune conditions like rheumatoid arthritis & ankylosing spondylitis is rising, fueling the growth of the biosimilars market. For the treatment of chronic pain in arthritis, biosimilars like infliximab-dyyb (Inflectra), infliximab-axxq (Avsola), infliximab-qbtx (Ixifi), and infliximab-abda (Renflexis) are used. Moreover, the number of orthopedic hospitals and diagnostic facilities is growing, which helps with disease diagnosis and treatment rates. As a result, the prevalence of debilitating autoimmune diseases is rising, and hospitals are becoming more numerous.
Diabetes incidence is steadily increasing, which is boosting the demand for insulin biosimilars. In addition, diabetes patients have a cost-effective option in the form of biosimilar insulin analogs. Because of the rising prevalence of diabetes as well as recent product approvals, the market for biosimilars is expanding.
Europe's diverse healthcare systems & sizable biosimilars markets serve as valuable case studies for various approaches to biosimilars policy. Sales of biosimilars reflect Europe's market leadership in terms of legislation and regulations. The biosimilars market in the region is more developed due to the high focus on healthcare. With more approved treatments than any other continent, Europe has established the benchmark. A large quantity of 10% of the region's total biologics market is currently made up of biosimilars, the majority of which have appeared in the last five years.
The Germany market dominated the Europe Biosimilars Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $3,862.8 million by 2028. The UK market is estimated to witness a CAGR of 22.6% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 24.6% during (2022 - 2028).
Based on Application, the market is segmented into Oncology Diseases, Blood Disorders, Chronic & Autoimmune Diseases and Others. Based on Type, the market is segmented into Monoclonal Antibodies, Granulocyte-Colony Stimulating Factor, Erythropoietin, Human Growth Hormone, Insulin and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Biocon Limited, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Intas Pharmaceutical Ltd, Novartis AG (Sandoz), Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd. and Fresenius SE & Co. KGaA
Scope of the Study
Market Segments covered in the Report:
By Application
- Oncology Diseases
- Blood Disorders
- Chronic & Autoimmune Diseases
- Others
- Monoclonal Antibodies
- Granulocyte-Colony Stimulating Factor
- Erythropoietin
- Human Growth Hormone
- Insulin
- Others
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Amgen, Inc.
- Biocon Limited
- Dr. Reddy’s Laboratories Ltd.
- Eli Lilly and Company
- Intas Pharmaceutical Ltd
- Novartis AG (Sandoz)
- Merck & Co., Inc.
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Fresenius SE & Co. KGaA
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
- Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 Europe Biosimilars Market, by Application
- 1.4.2 Europe Biosimilars Market, by Type
- 1.4.3 Europe Biosimilars Market, by Country
- 1.5 Methodology for the research
- Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market Composition & Scenario
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
- Chapter 3. Competition Analysis - Global
- 3.1 KBV Cardinal Matrix
- 3.2 Recent Industry Wide Strategic Developments
- 3.2.1 Partnerships, Collaborations and Agreements
- 3.2.2 Product Launches and Product Expansions
- 3.2.3 Acquisition and Mergers
- 3.2.4 Approvals and Trials
- 3.3 Top Winning Strategies
- 3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
- 3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, Jun – 2022, Aug) Leading Players
- Chapter 4. Europe Biosimilars Market by Application
- 4.1 Europe Oncology Diseases Market by Country
- 4.2 Europe Blood Disorders Market by Country
- 4.3 Europe Chronic & Autoimmune Diseases Market by Country
- 4.4 Europe Others Market by Country
- Chapter 5. Europe Biosimilars Market by Type
- 5.1 Europe Monoclonal Antibodies Market by Country
- 5.2 Europe Granulocyte-Colony Stimulating Factor Market by Country
- 5.3 Europe Erythropoietin Market by Country
- 5.4 Europe Human Growth Hormone Market by Country
- 5.5 Europe Insulin Market by Country
- 5.6 Europe Others Market by Country
- Chapter 6. Europe Biosimilars Market by Country
- 6.1 Germany Biosimilars Market
- 6.1.1 Germany Biosimilars Market by Application
- 6.1.2 Germany Biosimilars Market by Type
- 6.2 UK Biosimilars Market
- 6.2.1 UK Biosimilars Market by Application
- 6.2.2 UK Biosimilars Market by Type
- 6.3 France Biosimilars Market
- 6.3.1 France Biosimilars Market by Application
- 6.3.2 France Biosimilars Market by Type
- 6.4 Russia Biosimilars Market
- 6.4.1 Russia Biosimilars Market by Application
- 6.4.2 Russia Biosimilars Market by Type
- 6.5 Spain Biosimilars Market
- 6.5.1 Spain Biosimilars Market by Application
- 6.5.2 Spain Biosimilars Market by Type
- 6.6 Italy Biosimilars Market
- 6.6.1 Italy Biosimilars Market by Application
- 6.6.2 Italy Biosimilars Market by Type
- 6.7 Rest of Europe Biosimilars Market
- 6.7.1 Rest of Europe Biosimilars Market by Application
- 6.7.2 Rest of Europe Biosimilars Market by Type
- Chapter 7. Company Profiles
- 7.1 Fresenius SE & Co. KGaA
- 7.1.1 Company Overview
- 7.1.2 Financial Analysis
- 7.1.3 Segmental and Regional Analysis
- 7.1.4 Research & Development Expenses
- 7.1.5 Recent strategies and developments:
- 7.1.5.1 Approvals and Trials:
- 7.1.5.2 Product Launches and Product Expansions:
- 7.1.5.3 Acquisition and Mergers:
- 7.2 Dr. Reddy’s Laboratories Ltd.
- 7.2.1 Company Overview
- 7.2.2 Financial Analysis
- 7.2.3 Segmental and Regional Analysis
- 7.2.4 Research & Development Expense
- 7.2.5 Recent strategies and developments:
- 7.2.5.1 Partnerships, Collaborations, and Agreements:
- 7.2.5.2 Product Launches and Product Expansions:
- 7.3 Pfizer, Inc.
- 7.3.1 Company Overview
- 7.3.2 Financial Analysis
- 7.3.3 Regional & Segmental Analysis
- 7.3.4 Research & Development Expense
- 7.3.5 Recent strategies and developments:
- 7.3.5.1 Approvals and Trials:
- 7.3.5.2 Product Launches and Product Expansions:
- 7.3.5.3 Acquisition and Mergers:
- 7.4 Amgen, Inc.
- 7.4.1 Company Overview
- 7.4.2 Financial Analysis
- 7.4.3 Regional Analysis
- 7.4.4 Research & Development Expenses
- 7.4.5 Recent strategies and developments:
- 7.4.5.1 Approvals and Trials:
- 7.4.5.2 Product Launches and Product Expansions:
- 7.4.5.3 Acquisition and Mergers:
- 7.5 Teva Pharmaceutical Industries Ltd.
- 7.5.1 Company Overview
- 7.5.2 Financial Analysis
- 7.5.3 Regional Analysis
- 7.5.4 Research & Development Expenses
- 7.5.5 Recent strategies and developments:
- 7.5.5.1 Partnerships, Collaborations, and Agreements:
- 7.5.5.2 Approvals and Trials:
- 7.5.5.3 Product Launches and Product Expansions:
- 7.6 Eli Lilly And Company
- 7.6.1 Company Overview
- 7.6.2 Financial Analysis
- 7.6.3 Regional Analysis
- 7.6.4 Research & Development Expenses
- 7.6.5 Recent strategies and developments:
- 7.6.5.1 Partnerships, Collaborations, and Agreements:
- 7.7 Merck & Co., Inc.
- 7.7.1 Company Overview
- 7.7.2 Financial Analysis
- 7.7.3 Segmental and Regional Analysis
- 7.7.4 Research & Development Expenses
- 7.7.5 Recent strategies and developments:
- 7.7.5.1 Product Launches and Product Expansions:
- 7.8 Novartis AG (Sandoz)
- 7.8.1 Company Overview
- 7.8.2 Financial Analysis
- 7.8.3 Segmental and Regional Analysis
- 7.8.4 Research & Development Expense
- 7.8.5 Recent strategies and developments:
- 7.8.5.1 Partnerships, Collaborations, and Agreements:
- 7.8.5.2 Approvals and Trials:
- 7.9 Biocon Limited
- 7.9.1 Company Overview
- 7.9.2 Recent strategies and developments:
- 7.9.2.1 Partnerships, Collaborations, and Agreements:
- 7.9.2.2 Product Launches and Product Expansions:
- 7.9.2.3 Acquisition and Mergers:
- 7.10. Intas Pharmaceutical Ltd.
- 7.10.1 Company Overview
- 7.10.2 Recent strategies and developments:
- 7.10.2.1 Partnerships, Collaborations, and Agreements:
- 7.10.2.2 Product Launches and Product Expansions:
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook